Guggenheim Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-119,705
Closed -$2.15M 1978
2020
Q2
$2.15M Buy
119,705
+49,420
+70% +$687K 0.02% 857
2020
Q1
$501K Sell
70,285
-13,797
-16% -$172K 0.01% 1371
2019
Q4
$2.01M Buy
84,082
+18,170
+28% +$501K 0.02% 1043
2019
Q3
$1.77M Sell
65,912
-5,056
-7% -$142K 0.01% 1065
2019
Q2
$1.93M Sell
70,968
-810
-1% -$25.4K 0.02% 1073
2019
Q1
$2.49M Sell
71,778
-20,948
-23% -$604K 0.02% 979
2018
Q4
$1.81M Sell
92,726
-839
-0.9% -$17.3K 0.02% 1095
2018
Q3
$2.49M Buy
93,565
+17,835
+24% +$582K 0.02% 1117
2018
Q2
$2.86M Sell
75,730
-3,624
-5% -$139K 0.02% 1035
2018
Q1
$2.59M Buy
79,354
+11,544
+17% +$507K 0.01% 1448
2017
Q4
$3.3M Sell
67,810
-52,552
-44% -$2.66M 0.01% 1286
2017
Q3
$6.5M Buy
120,362
+34,213
+40% +$2.01M 0.02% 904
2017
Q2
$4.84M Buy
86,149
+9,820
+13% +$393K 0.01% 1031
2017
Q1
$2.99M Sell
76,329
-21,778
-22% -$694K 0.01% 1352
2016
Q4
$2.2M Sell
98,107
-5,372
-5% -$105K 0.01% 1601
2016
Q3
$2.35M Buy
103,479
+1,673
+2% +$39.3K 0.01% 1517
2016
Q2
$2.4M Buy
101,806
+5,157
+5% +$127K 0.01% 1449
2016
Q1
$1.97M Sell
96,649
-13,789
-12% -$437K 0.01% 1580
2015
Q4
$5.68M Sell
110,438
-39,690
-26% -$1.92M 0.02% 956
2015
Q3
$6.4M Sell
150,128
-15,988
-10% -$771K 0.02% 928
2015
Q2
$7.57M Buy
166,116
+15,406
+10% +$620K 0.02% 967
2015
Q1
$5.72M Buy
150,710
+13,711
+10% +$471K 0.01% 1106
2014
Q4
$3.88M Buy
+136,999
New +$3.81M 0.01% 1267

Guggenheim Capital's PTLA Position: Q3 2020 in Review

Guggenheim Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 119,705 shares — an estimated $2.15M sold.

Guggenheim Capital first reported a position in PTLA in Q4 2014 and held it in 23 quarters. The position peaked at $7.57M in Q2 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Guggenheim Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Guggenheim Capital sold 119,705 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $2.15M.
  • Guggenheim Capital first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 23 quarters.
  • Guggenheim Capital's Portola Pharmaceuticals, Inc. position peaked at $7.57M in Q2 2015.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Guggenheim Capital's 13F filing for Q3 2020, filed 13 Nov 2020.